HS235

BIOLOGICAL3 trials

Sponsors

35Pharma Inc

Conditions

Heart Failure With Preserved Ejection FractionOverweight and ObesityPulmonary Arterial HypertensionPulmonary Hypertension

Phase 1

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

CompletedNCT06714825

35Pharma IncOverweight and Obesity

Start: 2024-11-28End: 2025-12-02Updated: 2025-12-30

HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

RecruitingNCT07123779

35Pharma IncHeart Failure With Preserved Ejection Fraction, Pulmonary Hypertension

Start: 2026-08-01End: 2030-01-01Target: 126Updated: 2026-08-17

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

RecruitingNCT07143448

35Pharma IncPulmonary Arterial Hypertension

Start: 2026-08-19End: 2028-11-01Target: 90Updated: 2026-09-11